deltatrials
Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT05375994

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (RAMP204)

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination With Adagrasib in Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 204)

Sponsor: Mirati Therapeutics Inc.

Conditions Advanced Cancer KRAS Activating Mutation Malignant Neoplasm of Lung Malignant Neoplastic Disease Metastatic Cancer Non Small Cell Lung Cancer
Interventions avutometinib (VS-6766) and adagrasib
Updated 15 times since 2022 Last updated: May 13, 2025 Started: Aug 1, 2022 Primary completion: Dec 24, 2025 Completion: Jan 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Advanced Cancer and KRAS Activating Mutation and is currently ongoing. Mirati Therapeutics Inc. leads this study, which shows 15 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Nov 2022 · 2 months · monthly snapshot~Nov 2022 – ~Dec 2022 · 30 days · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Mar 2023 · 59 days · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Jun 2023 · 2 months · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Aug 2023 · 31 days · monthly snapshot~Aug 2023 – ~Jul 2024 · 11 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jun 2025 · 6 months · monthly snapshot~Jun 2025 – present · 13 months · monthly snapshot

Change History

15 versions recorded

  1. Jun 2025 — Present [monthly]

    Active Not Recruiting PHASE1/PHASE2

  2. Dec 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE1/PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  5. Aug 2023 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 10 earlier versions

  1. Jul 2023 — Aug 2023 [monthly]

    Recruiting PHASE1_PHASE2

  2. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  3. Apr 2023 — Jun 2023 [monthly]

    Recruiting PHASE1_PHASE2

  4. Mar 2023 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jan 2023 — Mar 2023 [monthly]

    Recruiting PHASE1_PHASE2

  6. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE1_PHASE2

  7. Nov 2022 — Dec 2022 [monthly]

    Recruiting PHASE1_PHASE2

  8. Sep 2022 — Nov 2022 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Jul 2022 — Sep 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

  10. Jun 2022 — Jul 2022 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mirati Therapeutics Inc.
  • Verastem, Inc.
Data source: Verastem, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations